Acadia's Nuplazid suffered a big loss in July after a late-stage trial as an add-on treatment for schizophrenia fell flat. But that study wasn't Nuplazid's last go at the indication, and now a ...

RELATED: FDA endorses Acadia's Nuplazid after review of deaths tied to drug In the first quarter, Nuplazid raked in $63 million in global sales, a 29% increase over the previous year, Acadia said.

ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.

NUPLAZID will be available through a specialty pharmacy network. Patients and physicians can access information about NUPLAZID and NUPLAZIDconnect by visiting www.nuplazid.com or calling 844-737-2223.

NUPLAZID is administered orally once-a-day. ACADIA discovered NUPLAZID and holds worldwide rights to this new chemical entity. The trade name NUPLAZID has been provisionally accepted by the FDA.

Nuplazid could offer an important new therapy for the hallucinations, illusions, and delusions experienced by many people with Parkinson's disease.

The drug is pimavanserin, a daily pill sold as Nuplazid by Acadia Pharmaceuticals Inc. It was approved for Parkinson's-related psychosis in 2016 and is thought to work by blocking a brain chemical ...

For FY23, the company expects Nuplazid sales of $520-$550 million compared to a consensus of $569.16 million.

Nuplazid may be a success story in so far as the FDA approval is concerned, but by its very nature, it is a drug that will need some hard selling. ACAD identified some of the main features ...

Nuplazid is protected through a composition of matter patent that runs to 2021, as well as a use patent in PD to 2026. Investors have raised some concerns about safety, EU-market access and sales.

Q2 2025 Management View Catherine E. Owen Adams, CEO, stated that "Our second quarter performance reinforces the momentum we're building across all facets of our business from commercial strength to ...

Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company had reported earnings ...